Peptic Ulcers – Pipeline Review, H1 2012 by GlobalMarketsDirect

VIEWS: 3 PAGES: 62

Peptic Ulcers - Pipeline Review, H1 2012', provides an overview of the Peptic Ulcers therapeutic pipeline. This report provides information on the therapeutic development for Peptic Ulcers, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Peptic Ulcers. 'Peptic Ulcers - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

More Info
									                       Peptic Ulcers – Pipeline Review, H1 2012


                                                                                          Reference Code: GMDHC1993IDB
                                                                                              Publication Date: April 2012




Peptic Ulcers – Pipeline Review, H1 2012                                                      GMDHC1993IDB / Pub April 2012
© Global Markets Direct. This report is a licensed product and is not to be photocopied                             Page(1)
Peptic Ulcers – Pipeline Review, H1 2012




Table of Contents
Table of Contents ............................................................................................................................................................................... 2
    List of Tables ................................................................................................................................................................................. 5
    List of Figures ................................................................................................................................................................................ 5
Introduction......................................................................................................................................................................................... 6
    Global Markets Direct Report Coverage ........................................................................................................................................ 6
Peptic Ulcers Overview ...................................................................................................................................................................... 7
Therapeutics Development................................................................................................................................................................. 8
    An Overview of Pipeline Products for Peptic Ulcers ...................................................................................................................... 8
Peptic Ulcers Therapeutics under Development by Companies....................................................................................................... 10
Peptic Ulcers Therapeutics under Investigation by Universities/Institutes ........................................................................................ 12
Late Stage Products ......................................................................................................................................................................... 13
    Comparative Analysis .................................................................................................................................................................. 13
Mid Clinical Stage Products.............................................................................................................................................................. 14
    Comparative Analysis .................................................................................................................................................................. 14
Discovery and Pre-Clinical Stage Products ...................................................................................................................................... 15
    Comparative Analysis .................................................................................................................................................................. 15
Peptic Ulcers Therapeutics – Products under Development by Companies..................................................................................... 16
Peptic Ulcers Therapeutics – Products under Investigation by Universities/Institutes ...................................................................... 17
Companies Involved in Peptic Ulcers Therapeutics Development ................................................................................................... 18
    Sequella, Inc. ............................................................................................................................................................................... 18
    AstraZeneca PLC ........................................................................................................................................................................ 19
    Takeda Pharmaceutical Company Limited .................................................................................................................................. 20
    Daewoong Pharmaceutical Co., Ltd. ........................................................................................................................................... 21
    Eisai Co., Ltd. .............................................................................................................................................................................. 22
    POZEN Inc. ................................................................................................................................................................................. 23
    aRigen Pharmaceuticals, Inc. ...................................................................................................................................................... 24
    Vecta Ltd. .................................................................................................................................................................................... 25
    Medigreen Biotechnology Corporation ........................................................................................................................................ 26
Peptic Ulcers – Therapeutics Assessment ....................................................................................................................................... 27
    Assessment by Monotherapy Products ....................................................................................................................................... 27
    Assessment by Route of Administration ...................................................................................................................................... 28
    Assessment by Molecule Type .................................................................................................................................................... 30
Drug Profiles..................................................................................................................................................................................... 32
    TAK-438 - Drug Profile ................................................................................................................................................................ 32
         Product Description................................................................................................................................................................. 32
         Mechanism of Action ............................................................................................................................................................... 32
         R&D Progress ......................................................................................................................................................................... 32
    IMD4 - Drug Profile ...................................................................................................................................................................... 33
         Product Description................................................................................................................................................................. 33
         Mechanism of Action ............................................................................................................................................................... 33
         R&D Progress ......................................................................................................................................................................... 33
    DWJ206 - Drug Profile ................................................................................................................................................................. 34



Peptic Ulcers – Pipeline Review, H1 2012                                                                                                           GMDHC1993IDB / Pub April 2012
© Global Markets Direct. This report is a licensed product and is not to be photocopied                                                                                                   Page(2)
Peptic Ulcers – Pipeline Review, H1 2012




        Product Description................................................................................................................................................................. 34
        Mechanism of Action ............................................................................................................................................................... 34
        R&D Progress ......................................................................................................................................................................... 34
    Aciphex Extended Release - Drug Profile ................................................................................................................................... 35
        Product Description................................................................................................................................................................. 35
        Mechanism of Action ............................................................................................................................................................... 35
        R&D Progress ......................................................................................................................................................................... 35
    Nexium - Drug Profile .................................................................................................................................................................. 37
        Product Description................................................................................................................................................................. 37
        Mechanism of Action ............................................................................................................................................................... 37
        R&D Progress ......................................................................................................................................................................... 37
    SQ 109 - Drug Profile .................................................................................................................................................................. 38
        Product Description................................................................................................................................................................. 38
        Mechanism of Action ............................................................................................................................................................... 38
        R&D Progress ......................................................................................................................................................................... 38
    PA32540 - Drug Profile ................................................................................................................................................................ 40
        Product Description................................................................................................................................................................. 40
        Mechanism of Action ............................................................................................................................................................... 40
        R&D Progress ......................................................................................................................................................................... 40
    ARH-1029 - Drug Profile .............................................................................................................................................................. 41
        Product Description................................................................................................................................................................. 41
        Mechanism of Action ............................................................................................................................................................... 41
        R&D Progress ......................................................................................................................................................................... 41
    Vecam - Drug Profile ................................................................................................................................................................... 42
        Product Description................................................................................................................................................................. 42
        Mechanism of Action .............................................................................................
								
To top